ALUNBRIG® (brigatinib) Expert Opinion Video Series: Intracranial efficacy of ALUNBRIG in patients with ALK+ aNSCLC
Prescribing information is available at the top of the page.
Listen to Prof Samreen Ahmed highlight the impact of brain metastases on quality of life in patients with ALK+ aNSCLC and why intracranial monitoring and management is important in these patients.
Prof Ahmed reviews ALUNBRIG’s intracranial efficacy vs crizotinib in patients with ALK+ aNSCLC from the pivotal ALTA-1L trial and discusses why ALUNBRIG could be a suitable treatment option in patients with ALK+ aNSCLC.
ALK, anaplastic lymphoma kinase; ALK+, ALK-positive; aNSCLC, advanced non-small cell lung cancer.
To enjoy the full experience of OncoConnect, including the ability to like and bookmark content for easy access via your account section, please register or login now.
